CoChat

Cell Therapy as Target Therapy against Colon Cancer Stem Cells

Open access
Garza Treviño, Elsa N., Quiroz Reyes, Adriana G., Rojas Murillo, Juan Antonio, de la Garza Kalife, David A, Delgado Gonzalez, Paulina, Islas, Jose F., Estrada Rodriguez, Ana Esther, Gonzalez Villarreal, Carlos A. · 2023 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Abstract

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development. Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs. We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24098163

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cancer stem cell surface markers and their antitumoral mechanisms. EGFR = epidermic growth factor receptor; PI3K = Phosphatidylinositol 3 kinase; AKT = protein kinase B; HER2 = human epidermal growth factor receptor 2; ERK = extracellular signal-regulated kinases; RSK = ribosomal S6 kinase; EpCAM = epithelial cell adhesion molecule; EpEX = EpCAM extracellular domain; EpICD = EpCAM intracellular domain; FHL2 = four and a half LIM domains protein 2; DR4/5 = death receptor 4/5; TAF1 BETA = TATA-box binding protein associated factor 1; NKG2R = natural killer group 2 receptor; NKG2L = natural killer group 2 ligand; MUC-1 = mucin 1; HIF-α = hypoxia-inducible factor; STAT1 = signal transducer and activator of transcription 1.
Figure 1 Cancer stem cell surface markers and their antitumoral mechanisms. EGFR = epidermic growth factor receptor; PI3K = Phosphatidylinositol 3 kinase; AKT = protein kinase B; HER2 = human epidermal growth factor receptor 2; ERK = extracellular signal-regulated kinases; RSK = ribosomal S6 kinase; EpCAM = epithelial cell adhesion molecule; EpEX = EpCAM extracellular domain; EpICD = EpCAM intracellular domain; FHL2 = four and a half LIM domains protein 2; DR4/5 = death receptor 4/5; TAF1 BETA = TATA-box binding protein associated factor 1; NKG2R = natural killer group 2 receptor; NKG2L = natural killer group 2 ligand; MUC-1 = mucin 1; HIF-α = hypoxia-inducible factor; STAT1 = signal transducer and activator of transcription 1.CC BY · PubMed Central
Figure 2 Schematic steps to consider for the selection of cell therapy as a treatment for CRC.
Figure 2 Schematic steps to consider for the selection of cell therapy as a treatment for CRC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 140 references

Research works printed but not linked: 1

  1. Abbas, A.K., Lichtman, A.H., and Pober, J.S. (1997). Cellular and Molecular Immunology, W.B. Saunders Company.

Cited by

See all 24

Metadata

Authors
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A.
Affiliations
  • Laboratorio de Terapia Celular, Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Av. Dr. José Eleuterio González 235, Monterrey 64460, Nuevo León, Mexico
  • Departamento de Ciencias Básicas, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, Ignacio Morones Prieto 4500. Jesus M. Garza, San Pedro Garza García 66238, Nuevo León, Mexico
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-05-03
Volume
24
Issue
9
Pages
8163
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4368367175
Cited by
24
References
140
Citations by year
2026: 5 · 2025: 12 · 2024: 7
FWCI
0.78
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
colorectal cancer, cancer stem cells, cell therapy, cellular immunotherapy, tumor recurrence, metastasis, treatment resistance, T cells, natural killer cells, macrophages, stem cell therapy, tumor microenvironment, combination therapy
MeSH terms
Colonic Neoplasms, Humans, Immunotherapy, Neoplasm Recurrence, Local, Neoplastic Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell Therapy as Target Therapy against Colon Cancer Stem Cells. https://app.cochat.ai/papers/10.3390/ijms24098163
The paper
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023). Cell Therapy as Target Therapy against Colon Cancer Stem Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098163

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.